Theranostics Explained

Theranostics Explained is the plain-English guide to a class of targeted radiation therapies that find cancer using a matched imaging molecule and treat it with a paired therapeutic molecule, delivering lethal radiation only where tumor cells sit.

Theranostics pairs a matched imaging molecule with a therapeutic molecule so radiation goes only where the cancer sits. Pluvicto and Lutathera are the modern flagships, following a lineage that started with radioactive iodine at Massachusetts General Hospital in 1941. This book walks curious general readers, newly diagnosed patients and their families, and healthcare professionals through the science, the trial data from VISION and NETTER-1 , the isotope supply chain, the real patient pathway, the honest limits, and the field's next decade. You will finish with a durable mental model of one of the fastest moving frontiers in oncology, told through a composite Northshore Nuclear Medicine team so every mechanism connects to a real clinical scene.

Inside this book, readers will learn how to:how a theranostic pair finds a tumor and treats it using matched imaging and therapeutic molecules.what Pluvicto, Lutathera, and Xofigo actually do inside the body and which patients qualify for each.the physics of beta emitters like Lu-177 and alpha emitters like Ac-225 and why particle range shapes design.how the isotope supply chain and hot lab work, and why manufacturing is often the real bottleneck.the full patient pathway from oncologist referral through scan, authorization, infusion, and side effects.the next wave of targets in trials, including FAP, HER2, GRPR, CAIX, and DLL3 , and what alpha therapy could unlock.where theranostic thinking is spreading beyond oncology into rheumatology, cardiology, and neurology. The composite Northshore Nuclear Medicine team includes a physician, a hot lab manager, a medical physicist, a nurse coordinator, and a patient navigator. Every claim in the book is anchored in current 2026 clinical practice, current FDA labels, and current published trial numbers, so you finish with the durable mental model needed to read the field honestly and be a fully informed member of your own care team when a theranostic option enters the conversation.